ONC: Rounding Bottom detected on 6 Nov 2026

All prices, scores, and news on this page reflect data available before market open on .

Free example: 1 of 48 setups from the 6 Nov 2026 scan. Subscribers get the full list every trading day by 6 AM ET.

On 6 Nov 2026, our scan flagged ONC as a rounding bottom setup scoring 74 out of 98 (Good tier), with a 70% win probability based on our historical pattern database and a 0.89 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $387.25, the conservative target is $405.99 with a stop at $366.21.

74 of 98
Good
70%
High
0.89 : 1
$18.74 to target $21.04 to stop
Swing Trading Plan
Entry
$387.25
$405.99
$366.21
2-8 trading days
Exp. Reward
+$10.40
Exp. Risk
-$5.00

Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.

Current Setup
ONC is forming a rounding bottom pattern with excellent structure (15.0/15) as it consolidates near current resistance at $362.14. The pattern shows moderate breakout potential (10.0/13) and volume support (10.15/12), yielding a solid overall pattern quality score of 74.15/98. Current price of $387.25 sits 4.38% below the 52-week high, positioned in the upper half of the trading range (52.49% above 52-week low). RSI at 60.9 is neutral, not overbought. Volume has surged 2.27x average on elevated relative strength, signaling institutional accumulation. The pattern suggests a move toward the conservative target of $405.99.
Stock Context
BeiGene reached a clear operational inflection point in Q3 2026, with global revenue rising 34% year-over-year to $1.9 billion. Q3 revenue of $1.89 billion exceeded UBS Group's forecast of $1.73 billion and market consensus of $1.76 billion. The company raised its 2026 guidance, increasing revenue forecast to a range of $6.9 billion to $7.0 billion. An FDA priority review for the BRUKINSA combination in first-line mantle cell lymphoma drove ONC up 6.42% on November 4. UBS Group maintained its Buy rating and top-pick status, raising the price target from $467 to $529. These recent catalysts—strong earnings beat, guidance raise, and FDA approval pathway—explain the upward price action forming this rounding bottom consolidation.
What to Expect
A successful rounding bottom breakout would target $405.99 (conservative measure), representing approximately 4.8% upside from current levels. Breakout confirmation requires sustained volume above the 2.27x relative volume currently observed, with price closing above the $362.14 resistance level on elevated trading. The win probability score of 70.3% suggests favorable odds for pattern completion. Invalidation occurs decisively below the $253.95 key support level, which represents a 34% decline from current price—establishing a well-defined risk/reward boundary for the setup.
Risk Factors
Biotechnology sector carries inherent regulatory and trial execution risk despite strong recent catalysts. The P/E ratio of 66.36 reflects stretched valuation heading into an earnings cycle—limited upside cushion if growth disappoints. Share-based compensation of $393 million for the nine months ended September 2026 suppresses earnings quality, representing roughly 46% of GAAP net income. While beta of 0.18 is historically low, healthcare volatility can spike on clinical data or regulatory news. No immediate downgrades detected, but sector regime is bearish (-0.69), conflicting with the bullish sector context (0.84), creating macro crosscurrents that could disrupt pattern momentum if broad market sentiment deteriorates.
How We Find and Score This Setup
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is ONC a good swing trade?
ONC scored 74 out of 98 on our rounding bottom scan, with a 70% historical win probability over a 2-8 trading days hold. Good setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $387.25, with a conservative target of $405.99 and a stop loss at $366.21.
What would invalidate this rounding bottom setup?
A close below the stop loss at $366.21 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical rounding bottom setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bearish -0.69
-1.0 0 +1.0
Health Care Sector
Bullish 0.85
-1.0 0 +1.0
Other Patterns Detected Today
Bull Flag
39 days in pattern
Weak 23.4
Overall Score
35 of 40
Strong
Pattern Quality
16 of 20
Strong
Setup
13 of 20
Moderate
R/R
10 of 18
Fair
Context
Pattern Quality Score
15 of 15
Exceptional
Structure
10 of 13
Good
Breakout
10 of 12
Strong
Volume
Recent Performance
+4.2%
1W
+1.3%
2W
+6.4%
1M
+11.2%
3M
Momentum & Trend
RSI (14)
60.9
Neutral
MACD Histogram
+0.19
Bullish
Bollinger Band Position
87.3%
Upper Zone
Volatility & Risk
20-Day Volatility
0.41
High
ATR %
3.4%
Medium
Beta
0.18
Defensive
Volume Analysis
Volume Ratio
2.27x
Very High
20-Day Avg Vol
423K
shares / day
Current Volume
960K
shares traded
Price Levels
Target
$405.99
52W High
$404.99
Current
$387.25
Stop Loss
$366.21
Resistance
$362.14
52W Low
$253.95
Support
$253.95
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.